Recon: FDA proposes annual COVID shots; Takeda pledges up to $1.13B for Hutchmed’s fruquintinib
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesGlobalMedical DevicesOtherPharmaceuticalsReconJoanne S. EglovitchBiologics/ biosimilars/ vaccinesGlobalMedical DevicesOtherPharmaceuticals